Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib [0.03%]
ADAURA研究启示：采用辅助奥希替尼时代，是否可以摒弃EGFR突变阳性II-IIIa期NSCLC（含Ib）的以铂类为基础的化疗（伴有RB基因改变者未确定）
Shannon S Zhang,Sai-Hong Ignatius Ou
Shannon S Zhang
Adjuvant cisplatin-based chemotherapy is considered the standard of care for resected stage IB (tumor ≥ 4m)-IIIA non-small cell lung cancer (NSCLC). The ADAURA trial is a randomized placebo-controlled Phase III trial that demonstrated stat...
ORIENT-31 as the Sakigake "Charging Samurai" Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the "Meiji Modernization" of Post-3G EGFR TKI Progression? [0.03%]
ORIENT-31作为Sakigake“蓄势待发的武士”应运而生，基于IMpower150模式，MARIPOSA-2研究能否在三代EGFR-TKI经治人群这一“明治维新”中大放异彩？
Misako Nagasaka,Sai-Hong Ignatius Ou
Misako Nagasaka
Tyrosine kinase inhibitors (TKIs) have become the preferred first line therapy for those patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Given superior progression free survival ...
An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma [0.03%]
恶性胸膜间皮瘤的新兴治疗选项最新进展
Alexander Davis,Helen Ke,Steven Kao et al.
Alexander Davis et al.
The treatment paradigm for malignant pleural mesothelioma (MPM) has changed little in the last 18 years. Radical intent treatment, consisting of surgical resection, radiotherapy and chemotherapy, has been offered to a highly select few; how...
The Role of Whole Exome Sequencing in Distinguishing Primary and Secondary Lung Cancers [0.03%]
全外显子测序在区分原发性和继发性肺癌中的作用
Natalie I Vokes,Jianjun Zhang
Natalie I Vokes
Non-small cell lung cancer (NSCLC) that presents with multiple lung tumors (MLTs) poses a challenge to accurate staging and prognosis. MLTs that arise as clonally related secondary metastases from a common primary are higher stage and often...
Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer [0.03%]
Amivantamab(JNJ-61186372)在EGFR外显子20插入突变的非小细胞肺癌中的研究进展
Danielle Brazel,Misako Nagasaka
Danielle Brazel
Non-small cell lung cancer (NSCLC) patients demonstrating sensitizing oncogenic driver mutations have derived clinical benefit from targeted therapy. EGFR mutations constitutively activate the signaling pathway, leading to prosurvival and a...
Orla Fitzpatrick,Jarushka Naidoo
Orla Fitzpatrick
Immunocheckpoint inhibitors (ICIs) have altered the treatment landscape of a wide range of malignancies, including non-small cell lung cancer (NSCLC). This class of agents inhibits the interaction between PD1 and PDL1, and was shown to be e...
Spotlight on Sotorasib (AMG 510) for KRAS G12C Positive Non-Small Cell Lung Cancer [0.03%]
索托拉西布(Sotorasib, AMG 510)治疗KRAS G12C阳性非小细胞肺癌的亮点
Shannon S Zhang,Misako Nagasaka
Shannon S Zhang
Mutations in codon 12 of KRAS have been identified in 13% of non-small cell lung cancer patients. Developing targeted therapies against KRASG12C mutation has proven to be challenging due to the abundance of GTP in the cytoplasm, rapid hydro...
Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer [0.03%]
聚焦于曲妥珠单抗德鲁特坎（DS-8201，T-DXd）在HER2突变阳性非小细胞肺癌中的应用
Ibrahim Azar,Samer Alkassis,Jami Fukui et al.
Ibrahim Azar et al.
Human epidermal growth factor receptor 2 (HER2) is a proto-oncogene that, when mutated or overexpressed, plays an important role in oncogenesis. The landscape of HER2-positive breast cancer has changed dramatically over the past 2 decades w...
An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece [0.03%]
希腊真实世界临床环境中，阿法替尼治疗晚期表皮生长因子受体（EGFR）突变阳性非小细胞肺癌患者的分子流行病学和直接医疗费用评估观察性研究
Giannis Mountzios,Sofia Lampaki,Georgia-Angeliki Koliou et al.
Giannis Mountzios et al.
Purpose: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred first-line option for patients with advanced, EGFR-mutant non-small cell lung cancer (NSCLC). Afatinib, a second-generat...
An Update on the Use of Exhaled Breath Analysis for the Early Detection of Lung Cancer [0.03%]
呼出气分析在肺癌早期诊断中的应用进展
Nir Peled,Vered Fuchs,Emily H Kestenbaum et al.
Nir Peled et al.
Lung cancer has historically been the main responsible for cancer associated deaths. Owing to this is our current inability to screen for and diagnose early pathological findings, preventing us from a timely intervention when cure is still ...